文献速递神经肿瘤小儿神经外科与脑积水

髓母细胞瘤代谢与分子相关性的活体¹H-MRS分子分组识别

Metabolic and molecular correlates of medulloblastoma: Identification of molecular groups using in vivo 1H-MR spectroscopy.
PubMed 文献 · Neuro Oncol · 2026-01-01

该单中心回顾性研究分析95例儿童髓母细胞瘤患者预处理¹H-MRS数据,评估活体质子磁共振波谱能否无创提供代谢标志物以支持术前分子分组。结果显示不同分子组间牛磺酸、肌酸、胆碱、谷氨酸和GABA存在显著差异,活体模式与离体NMR定性一致,提示¹H-MRS可作为辅助术前分层的可行影像生物标志物。

要点

  • ¹H-MRS可在常规MRI中增加约5分钟扫描,无创获取髓母细胞瘤代谢谱。
  • 牛磺酸在group 3和group 4相对SHH升高,SHH肌酸较低,WNT胆碱和GABA升高。
  • 活体代谢模式与离体高分辨HR-MAS NMR定性一致,支持术前分子分层。

核心结论

  • 活体¹H-MRS是广泛可用、临床可行的影像生物标志物,可辅助髓母细胞瘤术前分子分层。

研究设计与样本

  • 单中心回顾性研究,分析95例儿童髓母细胞瘤患者预处理¹H-MRS数据,中位年龄7.4岁,56例男性。
  • 采用单体素点分辨波谱(TE=35 ms,TR=1.5-2.0 s),在常规临床MRI中采集,约增加5分钟扫描时间。
  • 使用自动谱拟合定量绝对代谢物浓度和选定比值,按分子组比较(group 3 n=22;group 4 n=35;SHH n=26;WNT n=12)。
  • 组间差异采用Kruskal-Wallis检验及Dunn事后校正,并与既往离体高分辨HR-MAS NMR结果进行定性一致性评估。

主要发现

  • 各分子组间观察到显著代谢差异,牛磺酸、肌酸、胆碱、谷氨酸和γ-氨基丁酸(GABA)的组效应强(均P < .0015)。
  • 牛磺酸在group 3和group 4相对SHH升高(log₂FC=1.77和1.40,校正P < 4×10⁻⁵)。
  • SHH肿瘤肌酸低于group 3、group 4和WNT(校正P < .05)。
  • 谷氨酸在SHH高于WNT,WNT肿瘤胆碱和GABA相对其他组升高(校正P < .05)。
  • 活体¹H-MRS模式与离体NMR发现定性一致。

临床怎么用

  • 可将¹H-MRS作为常规MRI的补充序列,约增加5分钟扫描,用于髓母细胞瘤术前无创代谢评估。
  • 关注牛磺酸、肌酸、胆碱、谷氨酸和GABA等代谢物差异,辅助提示分子分组方向。
  • ¹H-MRS结果应与现有诊断流程互补,支持术前分层和治疗规划。

局限性

  • 单中心回顾性设计,样本量有限。
  • 活体与离体NMR仅进行定性一致性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate molecular classification of medulloblastoma is critical for prognosis and treatment planning, but current methods rely on surgical tissue sampling and molecular profiling. This study evaluated whether in vivo proton MR spectroscopy (¹H-MRS) can provide noninvasive metabolic markers to support presurgical molecular group stratification. METHODS: In this single-center retrospective study, pretreatment ¹H-MRS data were analyzed from 95 pediatric patients with medulloblastoma (median age 7.4 years; 56 male). Single-voxel point-resolved spectroscopy (TE = 35 ms, TR = 1.5-2.0 s) were acquired during routine clinical MRI, adding approximately 5 minutes of scan time. Absolute metabolite concentrations and selected ratios were quantified using automated spectral fitting. Metabolic profiles were compared across molecular groups (group 3, n = 22; group 4, n = 35; sonic hedgehog [SHH], n = 26; wingless [WNT], n = 12) and assessed for qualitative concordance with prior ex vivo high-resolution HR-MAS NMR findings. Group differences were tested using Kruskal-Wallis with Dunn post hoc correction. RESULTS: Significant metabolic differences were observed across molecular groups, with strong group effects for taurine, creatine, choline, glutamate, and γ-aminobutyric acid (GABA) (all P < .0015). Taurine was elevated in group 3 and group 4 relative to SHH (log₂FC = 1.77 and 1.40, adjusted P < 4 × 10⁻⁵). SHH tumors exhibited lower creatine compared with group 3, group 4, and WNT (adjusted P < .05). Glutamate was higher in SHH than in WNT, while WNT tumors showed increased choline and GABA relative to other groups (adjusted P < .05). In vivo patterns were qualitatively concordant with ex vivo NMR findings. CONCLUSIONS: In vivo ¹H-MRS is a widely available, clinically feasible imaging biomarker that complements existing diagnostics and supports presurgical stratification of medulloblastoma. Medulloblastoma is the most common malignant brain tumor in children and consists of 4 molecular types with different outcomes and treatments. Identifying the tumor type usually requires surgery and specialized laboratory testing. We studied whether proton MR spectroscopy, a technique added to routine MRI that measures natural chemicals within a tumor, could help classify these tumors before surgery. Each molecular group showed a distinct chemical pattern, including differences in taurine, creatine, glutamate, and GABA. These findings suggest that MR spectroscopy may provide a safe, widely available, noninvasive tool to support earlier tumor classification and treatment planning.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Tamrazi B, Markowitz AL, Margol AS, et al. Metabolic and molecular correlates of medulloblastoma: Identification of molecular groups using in vivo 1H-MR spectroscopy. Neuro Oncol. 2026. PMID: 42135953. doi:10.1093/neuonc/noag101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。